Early Use of CC-99282 with Rituximab After CAR T-Cell Therapy for Relapsed or Refractory Non-Hodgkins Lymphoma

What this Trial Is About

Researchers are evaluating the safety, side effects, and best dose of a combination treatment using CC-99282 and rituximab in patients with relapsed or refractory non-Hodgkin lymphoma who have had a sub-optimal response early after receiving CD19-directed CAR T-cell therapy. This phase I trial aims to better understand how this combination affects the immune system and tumor growth. The study also explores how the treatment impacts CAR T-cell activity and the tumor environment. Participants receive rituximab through an intravenous infusion on the first day of each 28-day cycle and take CC-99282 orally once daily for the first 14 days of each cycle. Rituximab is given for up to 6 cycles, while CC-99282 can be continued for up to 26 cycles unless the disease progresses or unacceptable side effects occur. Patients may undergo biopsy at screening and have PETCT scans and blood samples collected throughout the study. During the trial, patients are regularly monitored with imaging and laboratory tests to assess disease response and progression. Researchers measure treatment safety, maximum tolerated dose, progression-free survival, overall survival, and immune cell activity. After treatment, participants continue follow-up visits for up to two years to assess long-term outcomes and any lasting effects of the therapy.

CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma